Big Pharma’s biotech shift means layoffs for chemists
Big Pharma’s biotech shift means layoffs for chemists
December 11, 2007
Looking back, 2007 will perhaps be remembered as the year Big Pharma moved away from chemical-based drugs and fully embraced the biologics revolution. AstraZeneca, Sanofi, and (most notably) Pfizer--among many others--have announced sweeping changes that involve boosting investment in biotech drugs. The shift is due to a number of factors. Many of the world’s biggest blockbuster drugs are coming off patent in the next few years, and there aren’t many pharmaceuticals in the pipelines to replace them; Generics are expected to cut $67 billion from top drug makers' annual U.S. sales between 2007 and 2012. Additional, biologics are far less susceptible to the generic competition that’s chipping away at Big Pharma’s bottom line...
article link
December 11, 2007
Looking back, 2007 will perhaps be remembered as the year Big Pharma moved away from chemical-based drugs and fully embraced the biologics revolution. AstraZeneca, Sanofi, and (most notably) Pfizer--among many others--have announced sweeping changes that involve boosting investment in biotech drugs. The shift is due to a number of factors. Many of the world’s biggest blockbuster drugs are coming off patent in the next few years, and there aren’t many pharmaceuticals in the pipelines to replace them; Generics are expected to cut $67 billion from top drug makers' annual U.S. sales between 2007 and 2012. Additional, biologics are far less susceptible to the generic competition that’s chipping away at Big Pharma’s bottom line...
article link
Posted on 13 Dec 2007 by cchr
